Collagen-based medical devices produced in bioreactors

• Grant number: 17/16057-2
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: February 01, 2020
• End date: January 31, 2024
• Field of knowledge: Interdisciplinary Subjects
• Principal Investigator: Andreas Kaasi
• Grantee: Andreas Kaasi
• Company: EVA Scientific Indústria, Comércio e Serviços Ltda
• CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais ; Atividades profissionais, científicas e técnicas não especificadas anteriormente ; Atividades de ensino não especificadas anteriormente
• City: São Paulo
• Associated researchers: André Luiz Jardini Munhoz ; Cecilia Amelia de Carvalho Zavaglia ; Eliana Aparecida de Rezende Duek ; Paulo Kharmandayan ; Rubens Maciel Filho
• Associated research grant: 14/22799-3 - Biofabrication of collagen-based artificial tissues in purpose-built bioreactors for regenerative medicine and in vitro testing, AP.PIPE
• Associated scholarship(s): 22/00737-2 - Innovation and business for collagen-based medical devices produced in bioreactors, BP.TT; 21/15137-8 - Collagen-based kits and medical devices, BP.TT; 21/09844-3 - Engineering activities for the project “Collagen-based medical devices produced in bioreactors”, BP.TT; + associated scholarships 21/04653-5 - Collagen-based kits and medical devices, BP.TT; 21/03150-0 - Scalability processes applied to collagen-based medical devices, BP.TT; 21/03153-9 - Alternative sources of biologic tissue and other collagens for use in medical devices, BP.TT; 20/06972-8 - Studies on collagen for medical device product development, BP.TT; 20/09021-4 - Collagen-based kits and medical devices, BP.TT; 20/06572-0 - Engineering activities for the project collagen-based medical devices produced in bioreactors, BP.TT; 20/07090-9 - Collagen-based kits and medical devices, BP.TT - associated scholarships

Abstract

The scientific theme of this project lies in the convergence of the areas Biofabrication, Tissue Engineering, Regenerative Medicine and Personalized Medicine, with innovative application of these areas of science to obtain products of: (1) collagen based medical devices, intended for therapeutic use In humans; (2) similar devices for the therapeutic use of animals, for the veterinary market; (3) reagents and consumables for research, including collagen used as a raw material for biofabrication of tissues (medical and veterinary devices), but which has commercial value as a final product, including for the In Vitro Testing market; And (4) bioreactor control equipment and software for research, where part of the technologies (used in this category for the production of advanced medical device products) are kept in commercial secrecy and part turned into end products for the advancement of other research and For the common good. In this way, Eva Scientific reveals its bold approach where the base technology for producing collagen and consumables promotes bioreactor technology, but leveraging to market collagen and consumables for research as independent products; In the same way, bioreactor and software technologies serve as a basis for biofabrication of fabrics and biofabrication, but which have commercial potential by themselves and are also marketed; And finally, since medical devices for human use will require validation in animal models, there is the potential for independent commercialization of the same technologies for human use, thus forming a pyramid of four hierarchical levels, each containing Associated product lines. In this case, biofabrication of tissues (products 1 and 2) based on collagen (3) using bioreactors (4), contrary to the conventional approach of producing a synthetic framework directly with a 3D printer with the bioprinting approach, bioreactors are produced With mold compartments made with 3D printing technology, where natural polymers like collagen come in and acquire the desired geometric shape, with development having an emphasis on the basic shapes of circle, square, rectangle, tube and bag / sphere. In parallel and / or in series, the events of cellular seeding and tissue conditioning occur, with software control of parameters such as flow, pH, stirring, temperature - refrigerated and heated, as well as non - invasive and invasive monitoring of tissue quality in terms Physical and biological / cellular. A system capable of integrating the processes of (1) making the framework, (2) cell seeding and (3) conditioning in a bioreactor, is something innovative and unprecedented, so far not seen in the areas of Biofabrication, Tissue Engineering and Regenerative Medicine. This new approach, integrating the various sub-processes of Tissue Engineering into a single system, can transform and positively impact the health of our country. (AU)